• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular outcomes of vildagliptin in patients with type  2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke
ConclusionsAmong patients with type  2 diabetes mellitus after a recent acute coronary syndrome or acute ischemic stroke, treatment with vildagliptin was not associated with increased risks of CV death, non‐fatal myocardial infarction, non‐fatal stroke and hospitalization for HF.
Source: Journal of Diabetes Investigation - June 16, 2019 Category: Endocrinology Authors: Dong ‐Yi Chen, Yan‐Rong Li, Chun‐Tai Mao, Chi‐Nan Tseng, I‐Chang Hsieh, Ming‐Jui Hung, Pao‐Hsien Chu, Chao‐Hung Wang, Ming‐Shien Wen, Wen‐Jin Cherng, Tien‐Hsing Chen Tags: Original Article Source Type: research

Cardiovascular Outcomes of Vildagliptin in Patients with Type 2 Diabetes Mellitus after Acute Coronary Syndrome or Acute Ischemic Stroke
ConclusionsAmong patients with T2DM after a recent ACS or AIS, treatment with vildagliptin was not associated with increased risks of CV death, nonfatal MI, nonfatal stroke, and hospitalization for HF.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - May 21, 2019 Category: Endocrinology Authors: Dong ‐Yi Chen, Yan‐Rong Li, Chun‐Tai Mao, Chi‐Nan Tseng, I‐Chang Hsieh, Ming‐Jui Hung, Pao‐Hsien Chu, Chao‐Hung Wang, Ming‐Shien Wen, Wen‐Jin Cherng, Tien‐Hsing Chen Tags: Original Article Source Type: research

Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus
ConclusionsLow ABI was associated with cardiovascular events and diabetic foot ulcer independently in patients with type 2 DM.
Source: Frontiers in Endocrinology - November 18, 2021 Category: Endocrinology Source Type: research

Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
Conclusions/interpretationIn individuals with diabetes, the use of GLP1RAs was associated with significantly lower risks of major adverse limb events when compared with the use of DPP4is. The reduction in risk was driven largely by reduced rate of amputations. Moreover, treatment with GLP1RAs was also associated with lower risks of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction and death from any cause. However, some unexplored confounding factors may exist in this observation study and future large-scale randomised controlled trials are needed.Graphical abstract
Source: Diabetologia - August 24, 2021 Category: Endocrinology Source Type: research

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research

A long-term quality-of-care score for predicting the occurrence of macrovascular diseases in patients with type 2 diabetes mellitus
Diabetes mellitus (DM) is prevalent worldwide, and the number of patients was estimated to be 382 million in 2013 and expected to rise to 592 million by 2035 [1]. In Taiwan, around 7% of the total population (about 1.6 million) had DM in 2012, 90% of whom had type 2 diabetes mellitus. DM has been among the top five leading causes of death in Taiwan for more than three decades and took up about 11.5% of the total healthcare expenditures in the recent years [2]. In addition, DM is associated with a 2-4 times higher risk of cardiovascular disease (CVD) and stroke, which are the leading causes of death and disability among peo...
Source: Diabetes Research and Clinical Practice - February 23, 2018 Category: Endocrinology Authors: Pi-I Li, Jian-Nan Wang, How-Ran Guo Source Type: research

Analysis of HLA Variants and Graves ’ Disease and Its Comorbidities Using a High Resolution Imputation System to Examine Electronic Medical Health Records
Hyperthyroidism is a prevalent endocrine disorder, and genetics play a major role in the development of thyroid-associated diseases. In particular, the inheritance of HLA has been demonstrated to induce the highest susceptibility to Graves’ disease (GD). However, thus far, no studies have reported the contribution of HLA to the development of GD and the complications that follow. Thus, in the present study, to the best of our knowledge, for the first time, a powerful imputation method, HIBAG, was used to predict the HLA subtypes among populations with available genome-wide SNP array data from the China Medical University...
Source: Frontiers in Endocrinology - March 7, 2022 Category: Endocrinology Source Type: research

Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
Conclusions/interpretationIn people with diabetes, GLP1RA use was associated with significantly reduced risks of MALE compared with SGLT2i within the first 2 years after initiation, especially among people with diabetic neuropathy.Graphical abstract
Source: Diabetologia - August 9, 2022 Category: Endocrinology Source Type: research

Pages: 1  2